To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.

Start Date10 Jun 2026

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

NCT07094893

/ Not yet recruitingPhase 4IIT

A Biomarker Enrichment Trial of Anti-EGFR Agents in Patients With Advanced Colorectal Cancer (aCRC) With Wild-type RAS and Right Primary Tumour Location (Right-PTL).

The aim of this trial is to assess the feasibility of EREG/AREG assessment as a clinical diagnostic standard, used to guide clinical decision making in right-PTL, RAS-wt aCRC. Further to this, the aim is to determine whether EREG/AREG status identifies right-PTL participants who will benefit from the addition of anti-EGFR therapy to first-line chemotherapy.

Start Date15 Apr 2026

Sponsor / Collaborator

Gruppo Oncologico del Nord-Ovest

[+1]

NCT07286149

/ Not yet recruitingPhase 1/2

KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn:
* About the safety of MK-1084 and if people tolerate it when taken with other treatments
* How many people have the cancer respond (get smaller or go away) to the treatments

Start Date23 Feb 2026

Sponsor / Collaborator

Merck Sharp & Dohme LLC

[+1]

100 Clinical Results associated with Cetuximab

100 Translational Medicine associated with Cetuximab

100 Patents (Medical) associated with Cetuximab

7,471

Literatures (Medical) associated with Cetuximab

01 Feb 2026·COMPUTATIONAL BIOLOGY AND CHEMISTRY

LHRCDA: Predicting associations between circRNA and drug sensitivity via learnable hypergraph reconstruction

Article

Author: Wang, Xu ; Li, Mingxuan ; Zhai, Hui ; Song, Jinmiao ; Wang, Jingshuai

Circular RNAs (circRNAs) play key roles in the development of various diseases and drug responses, and mining their potential association with drugs is of great significance in unraveling disease mechanisms and discovering new therapeutic targets. However, traditional hypergraph methods typically rely on a static composition strategy, which makes it challenging to dynamically adjust the structure according to the task, resulting in a limited ability to extract higher-order information. Accordingly, we present a learnable hypergraph reconstruction (LHRCDA) approach for predicting circRNA-drug sensitivity associations. Specifically, the hypergraph representation is initialized based on matrix decomposition, followed by a learnable hypergraph reconstruction mechanism to adaptively capture potential higher-order structural information. After reconstruction, a hierarchical hypergraph mapping approach encodes the hypergraph at multiple levels, thereby further enhancing the ability to model complex nonlinear interactions between hyperedges. To effectively integrate different view representations from heterogeneous graph and hypergraph views, we adopt a hierarchical perceptual fusion strategy that solves the problem of information redundancy or loss that exists in traditional single fusion methods. Ultimately, the fused node representations are nonlinearly mapped using an MLP to output the association probabilities between circRNAs and drugs. Experimental results show that the hypergraph approach based on higher-order structural modeling outperforms multiple existing state-of-the-art models in circRNA-drug sensitivity association prediction. In addition, case studies were conducted on the drugs vorinostat and cetuximab, further demonstrating the potential of our model as an efficient and reliable tool.

01 Feb 2026·OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA

Novel Treatment Approaches in Recurrent/Metastatic Squamous Head and Neck Cancer

Review

Author: Jiménez-Labaig, Pablo ; Llop, Sandra ; Micheletto, Ilaria ; Saba, Nabil F ; O'Leary, Ben

The prognosis of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) remains poor, with most patients presenting with primary or acquired resistance to immune checkpoint inhibitors (ICIs). Upon progression on ICIs, the only standard of care treatment options are chemotherapy ± cetuximab combinations with high toxicity rates and limited efficacy, underscoring the urgent need for more effective and tolerable therapeutic strategies. This review explores the landscape of rapidly evolving novel treatment approaches in recurrent/metastatic HNSCC, including ICI combinations, therapeutic vaccines, injectable drugs, bispecific antibodies, antibody-drug conjugates, multitargeted kinase inhibitors and new targeted therapy agents.

01 Feb 2026·Lancet Gastroenterology & Hepatology

Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials

Article

Author: Cao, Baoshan ; Li, Xiaoyan ; Ba, Yi ; Shi, Huaqiu ; Shen, Lin ; Sun, Xin ; Wang-Gillam, Andrea ; Liu, Lian ; Lu, Shuang ; Li, Wenhua ; Yin, Xianli ; Liang, Rong ; Hu, Changlu ; Li, Yongsheng ; Li, Zhen ; Wang, Zhenghang ; Zhang, Yanqiao ; Liang, Xinjun ; Li, Jian ; Luo, Suxia ; Li, Zhihua ; Li, Xingya ; Xiong, Jianping ; Zhu, Liangjun ; Song, Zhengbo ; Xia, Guohao ; Bai, Chunmei ; Zhong, Diansheng ; Fu, Qihan ; Huang, Jing ; Huang, Chenghui ; An, Guangyu ; Ding, Yuli ; Wang, Zhen ; Wang, Feng ; Pan, Wenhui ; Rao, Zhiyue ; Gu, Yanhong

BACKGROUND:

KRAS^G12C mutations are present in around 4% of patients with colorectal cancer and are associated with lower treatment response rates and overall survival. EGFR signalling has been identified as a primary mechanism of resistance to KRAS^G12C inhibitors. We aimed to evaluate the efficacy and safety of a novel, covalent, small molecule KRAS^G12C inhibitor, glecirasib (JAB-21822), as monotherapy or in combination with the anti-EGFR cetuximab, in patients with KRAS^G12C-mutated colorectal cancer.

METHODS:

JAB-21822-1002 was an open-label, non-randomised, dose escalation (phase 1) and expansion (phase 2a) trial evaluating glecirasib monotherapy in KRAS^G12C-mutated solid tumours. JAB-21822-1007 was an open-label, non-randomised, dose escalation (phase 1b) and expansion (phase 2) study evaluating glecirasib plus cetuximab in KRAS^G12C-mutated colorectal, small intestine, and appendiceal cancer. Adult participants (aged ≥18 years) were recruited in China from 17 hospitals for the monotherapy trial and 16 hospitals for the combination trial. Here, we report only on patients with colorectal cancer treated with oral glecirasib at the recommended phase 2 dose (800 mg once daily in 21-day treatment cycles [until disease progression, intolerable toxicity, investigator's discretion, or withdrawal of consent]), pooling phase 1 and 2 data together. In the combination trial, cetuximab was administered intravenously with an initial loading dose of 400 mg/m² in the first week, followed by 250 mg/m² every week or 500 mg/m² every 2 weeks. For this analysis, key eligibility criteria were histologically or cytologically confirmed locally advanced or metastatic colorectal cancer with KRAS^G12C mutation; Eastern Cooperative Oncology Group performance status of 0 or 1; and at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST). For phase 1 of both trials, patients must not have responded to, were not suitable for, or refused standard of care. For phase 2 of both trials, patients must have received at least first-line standard of care and had disease progression or intolerance. Primary endpoints for the monotherapy trial were safety (treatment-emergent adverse events, serious adverse events, treatment-related adverse events, dose-limiting toxicity, and clinically significant changes in vital signs, physical examination, and electrocardiography, and clinically significant unexpected laboratory values of grade ≥3) for phase 1 and objective response rate (complete and partial response) for phase 2a. Primary endpoints for the combination trial were dose-limiting toxicities, maximum tolerated dose, and recommended phase 2 dose for phase 1b and objective response rate for phase 2. The full analysis set was defined as patients with at least one measurable lesion at baseline who received at least one dose of glecirasib in the monotherapy trial, or at least one dose of glecirasib plus cetuximab in the combination trial. The safety analysis set was defined as patients who received at least one dose of glecirasib in the monotherapy trial, or at least one dose of glecirasib or cetuximab in the combination trial. The trials are registered with ClinicalTrials.gov (NCT05009329 and NCT05194995), and are active but no longer recruiting.

FINDINGS:

Between Oct 12, 2021, and Dec 4, 2023, 44 patients with colorectal cancer (27 male and 17 female) in the monotherapy trial received glecirasib 800 mg once daily and comprised the full analysis and safety analysis sets. Between Feb 17, 2022, and Feb 28, 2023, 47 patients with colorectal cancer (22 male and 25 female) in the combination trial received glecirasib 800 mg once daily plus cetuximab and comprised the safety analysis set. One patient was excluded from the full analysis set as they received glecirasib only. Data cutoff was June 30, 2024. Median follow-up was 21·9 months (IQR 20·0-25·5) in the monotherapy trial and 18·7 months (15·9-20·6) in the combination trial. In the monotherapy trial phase 1, 15 patients with colorectal cancer were enrolled. No dose-limiting toxicities, unexpected grade 3 or worse laboratory values, or changes in vital signs, physical examinations, or electrocardiography were observed. 15 (100%) patients had treatment-emergent adverse events (n=8 [53%] grade ≥3), 13 (87%) of 15 reported treatment-related adverse events (n=4 (27%) grade ≥3); five (33%) of 15 patients had serious treatment-emergent adverse events, none were treatment-related. In the combination trial phase 1b, six patients with colorectal cancer were enrolled. No dose-limiting toxicities were observed and the maximum tolerated dose was not reached. The recommended phase 2 dose was chosen as glecirasib 800 mg once daily. Objective response rate was 23% (95% CI 11-38; ten of 44 patients [ten partial responses]) in the monotherapy trial and 50% (35-65; 23 of 46 patients [23 partial responses]) in the combination trial. The most common treatment-related adverse events were anaemia (24 [55%]), blood bilirubin increased (23 [52%]), and conjugated bilirubin increased (17 [39%]) in the monotherapy trial, and rash (39 [83%]), blood bilirubin increased (29 [62%]), conjugated bilirubin increased (17 [36%]), alanine aminotransferase increased (16 [34%]), and anaemia (15 [32%]) in the combination trial. The incidence of grade 3 or 4 treatment-related adverse events was 20% (nine of 44) in the monotherapy trial and 19% (nine of 47) in the combination trial. Two (5%) of 44 patients in the monotherapy trial (febrile neutropenia, n=2) and four (9%) of 47 patients in the combination trial (interstitial lung disease [n=1], pleural effusion and pericardial effusion [n=1], pyrexia [n=1], and rash [n=1]) reported serious treatment-related adverse events. No treatment-related deaths were observed in either trial.

INTERPRETATION:

Glecirasib monotherapy and its combination with cetuximab represent potential treatment options for patients with advanced, refractory colorectal cancer harbouring KRAS^G12C mutations. The promising efficacy and safety support further exploration of glecirasib-based combinations in earlier lines of treatment.

FUNDING:

Jacobio.

TRANSLATION:

For the Mandarin translation of the abstract see Supplementary Materials section.

613

News (Medical) associated with Cetuximab

14 Jan 2026

·www.prnewswire.com

AVEO Oncology, an LG Chem company, Announces First Patient Dosed in Front-Line AML Combination Study of Ficlatuzumab

– Collaboration with Blood Cancer United® in its Beat AML® Master Clinical Trial – – AVEO's ficlatuzumab compound to be studied in combination with azacitidine and venetoclax in patients with AML in a Phase 1b/2 clinical trial – – First patient dosed into the Phase 1b/2 clinical trial – BOSTON, Jan. 14, 2026 /PRNewswire/ -- AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and venetoclax in patients that are 60 years of age or older with untreated acute myeloid leukemia (AML) through a Master Clinical Trial Collaboration Agreement with Blood Cancer United®, formerly the Leukemia & Lymphoma Society. As part of this strategic collaboration with Blood Cancer United, a global nonprofit focused on blood cancer patient support, research, and advocacy, Blood Cancer United will be sponsoring the clinical trial as a sub-study in their Beat AML® Master Clinical Trial, the first collaborative precision medicine clinical trial in a blood cancer, which tests multiple therapies in multiple study arms simultaneously. The Phase 1b/2 clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination as a potential treatment for AML. Ficlatuzumab is AVEO's investigational humanized IgG1 monoclonal antibody that is designed to bind to the hepatocyte growth factor (HGF) ligand and prevent it from signaling via the c-Met receptor. Early phase clinical trials evaluating ficlatuzumab in combination with cytarabine in AML reported a favorable safety profile with promising clinical activity, supporting ficlatuzumab for further study in AML patients, particularly in those who are considered unfit for standard intensive first-line therapy. "This is a significant milestone for AVEO and Blood Cancer United, who are both dedicated to improving patient outcomes through novel clinical research," said Michael P. Bailey, President and CEO of AVEO. "We welcome this partnership and are excited to collaborate on this important clinical trial as we continue to expand our efforts to address high unmet medical needs with our novel clinical stage portfolio of therapies." "The Beat AML Master Clinical Trial seeks to change the paradigm for how this deadly cancer is treated, using an innovative precision medicine protocol and implementing strategic partnerships," said Lore Gruenbaum, Ph.D, Chief Scientific Officer of Blood Cancer United. "Our collaboration with AVEO is a key next step for the trial and transforming patient care for adults with AML." About AVEO Pharmaceuticals, Inc. AVEO Pharmaceuticals, Inc., an LG Chem company, (AVEO) is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet need, including ficlatuzumab in HPV-negative refractory head and neck squamous cell carcinoma and rilogrotug (also known as AV-380) in cancer cachexia. AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO continues to operate under the AVEO Oncology, an LG Chem company, name. About LG Chem, Ltd. and LG Chem Life Sciences LG Chem is a leading global chemical company with a diversified business portfolio spanning across petrochemicals, advanced materials, and life sciences. LG Chem Life Sciences, the life sciences business division of LG Chem, is dedicated to developing and delivering innovative medicines across a broad range of therapeutic areas. Guided by its mission to transform people's lives through inspiring science and leading innovation, LG Chem Life Sciences is offering differentiated solutions to its customers. For more information, please visit . About Blood Cancer United® and the Beat AML® Master Clinical Trial Blood Cancer United (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. The organization's mission is to cure blood cancer and improve the quality of life of all patients and their families. To achieve it, Blood Cancer United brings together a community of people—patients and their families, volunteers, healthcare providers, scientists, staff, partners, fundraisers, and philanthropists—who believe all blood cancer patients deserve longer, fuller lives. For support and to learn more, visit . The Beat AML® Master Clinical Trial (NCT03013998), launched in 2016 by Blood Cancer United, is the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced genomic technology to match patients to the most promising targeted treatment based on their unique genetic mutations. The trial tests multiple therapies in multiple sub-studies simultaneously and has already generated strong results, demonstrating positive survival rates and better quality of life. Over the past decade, Beat AML has grown into a powerful ecosystem of pharma companies, genetic testing experts, data specialists, regulatory agencies, and other industry partners working toward better and safer treatments for patients with AML. For more information, visit . About Ficlatuzumab Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) immunoglobulin G1 inhibitory antibody that binds to the HGF ligand with high affinity and specificity. HGF is the natural ligand of c-Met and blocking HGF inhibits signaling through the HGF/c-Met signaling pathway. The U.S. Food and Drug Administration designated as a Fast Track development program the investigation of ficlatuzumab and ERBITUX® (cetuximab) for relapsed/recurrent HNSCC in September 2021, which is currently in a Phase 3 clinical study. Contacts Media: John F. Kouten JFK Communications, Inc. 908-227-4714 [email protected] SOURCE AVEO, an LG Chem company 21% more press release views with Request a Demo

Phase 3Fast Track

12 Jan 2026

·endpoints.news

Eisai licenses Nuvation lung cancer pill; Alnylam's stock dips after sales data report

Plus, news about Summit, Pfizer, Insmed, Bristol Myers Squibb, Lynk Pharmaceuticals, Stoke Therapeutics, UniQure, Teva, Royalty Pharma, Vibrant Therapeutics and Recludix Pharma: 💊 Nuvation Bio licenses lung cancer pill to Eisai : The Japanese company has obtained exclusive development, registration and sales rights to Nuvation’s Ibtrozi in Europe and Canada, as well as certain countries in the Middle East, Africa, Asia and Australasia. Eisai will pay €50 million ($58 million) upfront and up to €145 million in biobucks, plus double-digit tiered royalties. Nuvation will keep US rights to the pill, which is approved in the US, China and Japan for ROS1-positive non-small cell lung cancer. — Elizabeth Cairns 📉 Alnylam reveals preliminary Q4 sales, stock falls: The company said over the weekend that its TTR revenues, comprising Amvuttra and Onpattro, were $827 million and $32 million, respectively. In 2026, Alnylam is guiding toward combined sales of $4.4 billion and $4.7 billion for the two drugs. Alnylam’s stock $ALNY fell about 10% in Monday midmorning trading. — Max Gelman 🗂️ Summit asks FDA for lung cancer approval: The biotech submitted an FDA application for ivonescimab, its PD-1xVEGF bispecific antibody, in second-line patients with a specific form of lung cancer. Summit is expecting a decision in this year’s fourth quarter, if the FDA decides to review the application. An approval would mark the first for this new class of drugs, though analysts say the market opportunity in this population (EGFR-mutated non-small cell lung cancer) is relatively small. Separately, Summit also said it will test ivonescimab with a B7-H3 antibody-drug conjugate called risvutatug rezetecan, which is being developed by GSK. — Max Gelman 🌊 Pfizer’s Braftovi beats standard care in colorectal cancer : A new cut of data from Cohort 3 of the ongoing pivotal BREAKWATER trial showed an objective response rate of 64.4% for the BRAF inhibitor, used in combination with Erbitux and the chemo regimen known as FOLFIRI. Patients in the control arm, who received standard-of-care FOLFIRI with or without Avastin, had an ORR of 39.2%. Pfizer said the difference was clinically meaningful and statistically significant. Patients in the trial had not been treated before. The data were presented Monday at the 2026 ASCO GI confab. — Elizabeth Cairns Error: Survey not found. 🏷️ Insmed announces first full quarter sales for Brinsupri: The company’s preliminary figures show Brinsupri pulled in $144.6 million in 2025’s fourth quarter. Insmed secured FDA approval for the drug in August last year. Brinsupri is an oral, once-a-day treatment for non-cystic fibrosis bronchiectasis in adults and children 12 years and older. — Anna Brown 🫀 Bristol Myers Squibb gets a late-stage heart disease win in teens : Camzyos succeeded in a Phase 3 trial in 44 patients aged 12-17 with the heart muscle disorder obstructive hypertrophic cardiomyopathy. The cardiac myosin inhibitor showed a statistically significant improvement over placebo on a measure of obstructed blood flow at about six months, BMS said Monday. There were no new safety signals, and BMS intends to take the data to regulators, though it did not say when. — Elizabeth Cairns 🇨🇳 Lynk Pharmaceuticals’ arthritis pill hits in China-based trial : The Phase 3 trial of zemprocitinib in moderate to severe active rheumatoid arthritis met its primary and key secondary efficacy endpoints, the Hangzhou, China-based biotech said Monday. Of the patients given 12 mg of the JAK1 inhibitor twice daily, 79.1% had a 20% improvement in disease activity at about six months, versus 39.7% of those given placebo, a statistically significant difference. More patients given Lynk’s drug had a 50% improvement on the same measure. Rates of serious adverse events were similar in both arms. — Elizabeth Cairns ⏳ Stoke Therapeutics pulls forward Dravet development timeline: The biotech said a Phase 3 trial of its Biogen-partnered drug, called zorevunersen, is now expected to complete enrollment in the second quarter. The company is on track to start a rolling NDA submission in 2027, ahead of an expected readout in the middle of that year. In the meantime, the FDA has requested more information from Stoke, which is hoping to secure a faster pathway to approval in Dravet syndrome. — Ayisha Sharma 💼 UniQure secures FDA meeting for Huntington’s gene therapy: The Type A meeting will be spent discussing what sort of data package uniQure needs to support accelerated approval of AMT-130. The update seems to mark a step forward from November, when the biotech said the FDA no longer deemed its Phase 1/2 data compared to an external control sufficient for approval. — Ayisha Sharma 🖋️ Teva signs funding deal with Royalty Pharma: The Israeli biotech will receive $75 million in R&D funding to conduct a Phase 2b trial of its anti-IL-15 antibody, called TEV-‘408, in vitiligo. Royalty could also provide up to $425 million for Phase 3 development, depending on the results of that Phase 2b study. Royalty is eligible for milestone payments and a royalty on global sales. — Ayisha Sharma 💵 Pfizer Ventures joins $61M fundraise for Vibrant Therapeutics: The US-China biotech will use the proceeds to advance its pipeline, including its lead candidate for solid tumors, called VIB305. The candidate is currently in Phase 1 development in China and Australia, with US studies on the horizon. Pfizer Ventures chipped in as a new investor alongside several other backers. — Ayisha Sharma 💰 Recludix Pharma clinches $20M milestone from Sanofi: The payment was triggered because Recludix started dosing healthy volunteers in a Phase 1 trial of its STAT6 inhibitor, called REX-8756. Sanofi and Recludix’s deal , which dates back to 2023, features more than $1.2 billion in milestones. — Ayisha Sharma

Phase 3Clinical ResultDrug ApprovalPhase 1Phase 2

12 Jan 2026

·pmlive.com

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Pfizer’s Braftovi (encorafenib), in combination with Erbitux (cetuximab) and Folfiri (fluorouracil, leucovorin and irinotecan), has shown positive results in a new trial of patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Braftovi is an oral small molecule kinase inhibitor designed to specifically target BRAF V600E. Results from cohort 3 of the BREAKWATER trial showed that the Braftovi-Erbitux-Folfiri combination regimen demonstrated a clinically meaningful and statistically significant response rate in this patient group, compared with patients receiving Folfiri with or without bevacizumab. Within the Braftovi combination treatment arm, 57.4% of patients saw a response lasting six months or longer, compared with 34.5% of patients receiving Folfiri with or without bevacizumab. The Braftovi combination regimen demonstrated a safety profile consistent with each drug’s established safety profile, and no new safety signals were identified by the trial. The BREAKWATER trial is ongoing and is expected to be completed in 2027. CRC is the third most common cancer worldwide and the second leading cause of cancer-related deaths. Around 154,720 people in the US are expected to be diagnosed with CRC in 2025, and around 53,000 people in the US die from the disease annually. Additionally, 20% of all CRC patients see their disease metastasise or spread to other areas of the body. Approximately 8-12% of people with mCRC develop BRAF mutations, with BRAF V600E being the most common. Mortality risk in CRC patients with BRAF V600E mutation is over double that of patients without known mutation. Prior to December 2024 there were no approved biomarker-driven treatments for previously untreated mCRC with BRAF V600E mutations. Scott Kopetz, Professor and Deputy Chair of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center and co-principal investigator of the BREAKWATER trial, said: “These results represent a great advance for patients with BRAF V600E-mutant mCRC. We’ve seen this approach significantly increase the response compared to Folfiri with or without bevacizumab, and these responses were rapid and durable. “The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population.” Jeff Legos, chief oncology officer at Pfizer, added: “These results underscore the potential of Braftovi as a standard of care for patients with this aggressive cancer.” The data will be presented in an oral presentation at the 2026 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium.

Clinical ResultASCOPhase 3

100 Deals associated with Cetuximab

External Link

KEGG	Wiki	ATC	Drug Bank
D03455	Cetuximab	L01XC06	DB00002

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
BRAF V600E mutant Colorectal Cancer	China	Merck Europe BV	30 Sep 2025
RAS Wild Type Colorectal Cancer	Australia	Merck Healthcare Pty Ltd.	25 Sep 2007
Head and Neck Neoplasms	United States	Eli Lilly & Co.	01 Mar 2006
Metastatic Colorectal Carcinoma	European Union	Merck Europe BV	29 Jun 2004
Metastatic Colorectal Carcinoma	Iceland	Merck Europe BV	29 Jun 2004
Metastatic Colorectal Carcinoma	Liechtenstein	Merck Europe BV	29 Jun 2004
Metastatic Colorectal Carcinoma	Norway	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	European Union	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	Iceland	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	Liechtenstein	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	Norway	Merck Europe BV	29 Jun 2004
Colorectal Cancer	Switzerland	Merck & Co., Inc.	01 Dec 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenocarcinoma	Phase 3	United States	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	China	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	Japan	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	Argentina	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	Australia	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	Brazil	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	Finland	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	France	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	Germany	Merck Sharp & Dohme LLC	16 Jul 2025
Adenocarcinoma	Phase 3	Hong Kong	Merck Sharp & Dohme LLC	16 Jul 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04349267 (CTgov)	Phase 1/2	Advanced Malignant Solid Neoplasm	44	BMS-986315 (Part 1A BMS-986315-80 mg)	cynleusres = juzzcwtnbb adsgilqjjf (surwvtcime, ehxgdwxhji - vgjnncevbo) View more	-	17 Dec 2025
				BMS-986315 (Part 1A BMS-986315-200 mg)	cynleusres = flmqebvrvl adsgilqjjf (surwvtcime, zrkgxddelo - audctvvuaj) View more
CeRWIN (ESMO_ASIA2025)	Not Applicable	Squamous Cell Carcinoma of Head and Neck EGFR	136	Biosimilar cetuximab (alone or with chemotherapy/radiotherapy)	hhglqqshle(certfvexqp) = avmrtevopt zljnaicfeb (kkaxkekpzr ) View more	Positive	05 Dec 2025
NCT04607421 (BREAKWATER, ESMO_ASIA2025)	Phase 3	BRAF V600E mutant Colorectal Cancer First line BRAF V600E-mutant	225	Encorafenib + cetuximab	ywtlcbyyef(puqmcpgexa) = tnbxbfpgkr vhwwesmarc (acpoviwdjb, 4.1 - 16.1) View more	Positive	05 Dec 2025
				Encorafenib + cetuximab + mFOLFOX6	ywtlcbyyef(puqmcpgexa) = fljtilfrvy vhwwesmarc (acpoviwdjb, 13.9 - NE) View more
ESMO_ASIA2025	Not Applicable	RAS Wild Type Colorectal Cancer	101	Cetuximab + standard therapy	lkutfwrlrg(zfbgndvnrf) = nnroxhfoim dtxrvxdazi (sdeqpcapsp ) View more	Positive	05 Dec 2025
				Cetuximab + standard therapy (left-sided mCRC)	lkutfwrlrg(zfbgndvnrf) = pjzobsntmd dtxrvxdazi (sdeqpcapsp ) View more
ESMO_ASIA2025	Not Applicable	RAS Wild Type Colorectal Cancer First line	969	Panitumumab	cumdeblekj(ayutcajlsu) = hqujrnvsvm kmwclbqqnc (ejscoltxpp, 23.68 - 38.12) View more	Positive	05 Dec 2025
				Cetuximab	cumdeblekj(ayutcajlsu) = thbkjqxzlj kmwclbqqnc (ejscoltxpp, 25.17 - 31.36) View more
NCT05291156 (CAVE-2 GOIM, Pubmed \| Ann Oncol)	Phase 2	Metastatic Colorectal Carcinoma RAS \| BRAF	156	Cetuximab + Avelumab	pbxjpnyygr(yyjtpksugl) = fwrseufhzl makqqojjuy (dhunhuypxv, 12.1 - 18.3) View more	Negative	01 Dec 2025
				Cetuximab	pbxjpnyygr(yyjtpksugl) = ljydhufzbg makqqojjuy (dhunhuypxv, 11 - NE) View more
NCT05019534 (Pubmed \| J Transl Med)	Phase 1	BRAF V600E mutant Colorectal Cancer Second line BRAF V600E \| microsatellite stable (MSS)	12	Vemurafenib+cetuximab+camrelizumab	gwuumiseko(pwglwgylhv) = xfjlrzlqax pcplnhcmxz (anqlaslity ) View more	Positive	12 Nov 2025
NCT04607421 (BREAKWATER, ESMO2025)	Phase 3	BRAF V600E mutant Colorectal Cancer First line BRAF V600E-mutant	78	Encorafenib + cetuximab + mFOLFOX6	oykvlespjx(ccsoirenmv) = bnbdomhzwy vtneklifus (wtzwwfgjdn, 42.2 - 72.9) View more	Positive	17 Oct 2025
				Control (chemotherapy ± bevacizumab)	oykvlespjx(ccsoirenmv) = mtpzdgiths vtneklifus (wtzwwfgjdn, 23.0 - 50.8) View more
ESMO2025	Not Applicable	Squamous cell carcinoma of head and neck metastatic Second line	78	Carboplatin+Paclitaxel+Cetuximab	rhluidngzf(tjvapepvlu) = zzausirsgz uzxqntgunz (wcnhhtxlcf ) View more	Positive	17 Oct 2025
				Carboplatin+Paclitaxel+Cetuximab (immunotherapy alone (IO-A))	rhluidngzf(tjvapepvlu) = irojrodgad uzxqntgunz (wcnhhtxlcf ) View more
NCT04607421 (BREAKWATER, ESMO2025)	Phase 3	BRAF V600E mutant Colorectal Cancer First line BRAF V600E	637	Encorafenib + cetuximab (EC)	ovsjxeubfc(rbuinqssns) = ocspcrhqbg wxaohwvssn (evmzrxvqri ) View more	Positive	17 Oct 2025
				Encorafenib + cetuximab + mFOLFOX6 (EC+mFOLFOX6)	ovsjxeubfc(rbuinqssns) = xymucwchwi wxaohwvssn (evmzrxvqri ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis